Tibial nerve stimulation for overactive bladder

Percutaneous Tibial Nerve Stimulation (PTNS) for patients with overactive bladder syndrome: effect of number of sessions and gender

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15733799

Enrollment

Registered

2018-01-30

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Over active bladder syndrome Urological and Genital Diseases Over active bladder syndrome

Interventions

Participants are recruiting in accordance the inclusion criteria and provide consent to participate in the protocol. Data is collected about age, evolution time, voiding diary, OABq-SD questionnaire

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults (female and male) suffering refractory OAB syndrome, 8 or more micturitions in 24 hours and questionnaire OAB-q SF score = 20 points 2. No response to medication 3. Evolution time = 6 months 4. Agree to participate and sign informed consent

Exclusion criteria

Exclusion criteria: 1. Urinary tract infection 2. History of congenital urogenital disease, radiation, bladder cancer or litiasis 3. People who can not participate because of religious, cultural or mental reasons 4. People who can not participate because of do not sign informed consent or unwilling to participate in the protocol 5. Pregnancy 6. Age less than 18 years old 7. History of taking OAB medication for less than 2 weeks before to start PTNS

Design outcomes

Primary

Measure	Time frame
Bladder activity (nocturia, incontinence or urgency and frequency)is measured using the patient diaries for Group 1 and Placebo Group at baseline, 24 hours, one, three and six months and for Group 2 at baseline, one, three and six months.	—

Secondary

Measure	Time frame
1. Overactive bladder symptoms are measured using OABq-SF Questionnaire Part A for Group 1 and Placebo Group at baseline, 24 hours, one, three and six months and for Group 2 at baseline, one, three and six months. 2. Overactive bladder symptoms are measured using Perception of Bladder Condition (PPBC) Questionaire for Group 1 and Placebo Group at baseline, 24 hours, one, three and six months and for Group 2 at baseline, one, three and six months	—

Measure

Time frame

1. Overactive bladder symptoms are measured using OABq-SF Questionnaire Part A for Group 1 and Placebo Group at baseline, 24 hours, one, three and six months and for Group 2 at baseline, one, three and six months. 2. Overactive bladder symptoms are measured using Perception of Bladder Condition (PPBC) Questionaire for Group 1 and Placebo Group at baseline, 24 hours, one, three and six months and for Group 2 at baseline, one, three and six months

—

Countries

Mexico

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 7, 2026